PTC Therapeutics (PTCT) Revenue & Revenue Breakdown
PTC Therapeutics Revenue Highlights
Latest Revenue (Y)
$937.82M
Latest Revenue (Q)
$135.42M
Main Segment (Y)
Collaboration Revenue
Main Geography (Y)
United States
PTC Therapeutics Revenue by Period
PTC Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $937.82M | 34.20% |
2022-12-31 | $698.80M | 29.75% |
2021-12-31 | $538.59M | 41.45% |
2020-12-31 | $380.77M | 24.04% |
2019-12-31 | $306.98M | 15.96% |
2018-12-31 | $264.73M | 36.19% |
2017-12-31 | $194.39M | 135.04% |
2016-12-31 | $82.70M | 124.95% |
2015-12-31 | $36.77M | 60.11% |
2014-12-31 | $22.96M | -26.70% |
2013-12-31 | $31.33M | 8.85% |
2012-12-31 | $28.78M | -70.92% |
2011-12-31 | $98.96M | - |
PTC Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $135.42M | -27.47% |
2024-06-30 | $186.70M | -11.14% |
2024-03-31 | $210.12M | -31.57% |
2023-12-31 | $307.06M | 56.20% |
2023-09-30 | $196.58M | -8.06% |
2023-06-30 | $213.81M | -2.98% |
2023-03-31 | $220.38M | 31.64% |
2022-12-31 | $167.41M | -22.90% |
2022-09-30 | $217.13M | 31.17% |
2022-06-30 | $165.53M | 11.29% |
2022-03-31 | $148.74M | -9.98% |
2021-12-31 | $165.23M | 19.09% |
2021-09-30 | $138.74M | 18.91% |
2021-06-30 | $116.68M | -1.07% |
2021-03-31 | $117.94M | -0.78% |
2020-12-31 | $118.86M | 0.39% |
2020-09-30 | $118.40M | 57.37% |
2020-06-30 | $75.24M | 10.23% |
2020-03-31 | $68.26M | -29.24% |
2019-12-31 | $96.46M | 35.07% |
2019-09-30 | $71.42M | -16.49% |
2019-06-30 | $85.52M | 59.61% |
2019-03-31 | $53.58M | -37.94% |
2018-12-31 | $86.34M | 61.11% |
2018-09-30 | $53.59M | -22.04% |
2018-06-30 | $68.74M | 22.62% |
2018-03-31 | $56.06M | -28.15% |
2017-12-31 | $78.03M | 86.44% |
2017-09-30 | $41.85M | -12.74% |
2017-06-30 | $47.96M | 80.67% |
2017-03-31 | $26.55M | 5.38% |
2016-12-31 | $25.19M | 9.59% |
2016-09-30 | $22.99M | 47.04% |
2016-06-30 | $15.63M | -17.26% |
2016-03-31 | $18.89M | 24.17% |
2015-12-31 | $15.22M | 55.69% |
2015-09-30 | $9.77M | 53.49% |
2015-06-30 | $6.37M | 17.77% |
2015-03-31 | $5.41M | -53.40% |
2014-12-31 | $11.60M | 1355.71% |
2014-09-30 | $797.00K | -43.79% |
2014-06-30 | $1.42M | -84.50% |
2014-03-31 | $9.15M | 132.70% |
2013-12-31 | $3.93M | -74.57% |
2013-09-30 | $15.46M | 163.39% |
2013-06-30 | $5.87M | -3.37% |
2013-03-31 | $6.07M | 2.60% |
2012-12-31 | $5.92M | -2.06% |
2012-09-30 | $6.04M | -0.36% |
2012-06-30 | $6.06M | -43.60% |
2012-03-31 | $10.75M | - |
PTC Therapeutics Revenue Breakdown
PTC Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 19 | Dec 18 |
---|---|---|---|
Collaboration Revenue | $100.03M | - | - |
Manufacturing | $7.69M | - | - |
Product | - | $291.31M | - |
Grant And Collaboration | - | $15.67M | - |
Emflaza | - | - | $92.00M |
Translarna | - | - | $171.00M |
Early Stage Collaborations | - | - | $252.00M |
Licensing And Collaboration Agreement | - | - | $200.00K |
Grant | - | - | - |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Royalty | $61.37M | $4.09M | $696.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Manufacturing | $800.00K | $1.36M | $3.34M | $2.36M | $1.99M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Product | $135.42M | $103.11M | $91.28M | $107.26M | $82.71M | $75.24M | $68.20M | $81.41M | $71.37M | $85.48M | - | - | - | - | - | - | - | - | - |
Net product revenue | - | $177.60M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Grant And Collaboration | - | - | - | - | - | - | - | $7.52M | $35.00M | - | $63.00K | $15.05M | $47.00K | $46.00K | - | - | - | - | - |
Early Stage Collaborations | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $252.00M | - | - | - | - |
Licensing And Collaboration Agreement | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $100.00K | $87.50M | $100.00K | $100.00K | - |
Discovery Agreements | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Latest
PTC Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
United States | $531.66M | $218.30M | $187.30M | - | - |
Non-US | $406.16M | $288.60M | $236.00M | $190.30M | - |
Non Us | - | - | - | $194.40M | - |
U | - | - | - | $139.00M | - |
UNITED STATES | - | - | - | - | $116.68M |
Latest
Quarterly Revenue by Country
Country | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
---|---|---|---|---|---|---|---|---|---|
United States | $411.36M | $65.70M | $54.60M | $58.20M | $54.80M | $56.80M | $48.60M | $47.50M | - |
Non-US | $194.56M | $96.50M | $115.10M | $55.70M | $76.60M | $77.00M | $79.20M | $69.70M | - |
Non Us | - | - | - | - | - | - | - | - | $67.20M |
U | - | - | - | - | - | - | - | - | $47.10M |
Latest
PTC Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
SRPT | Sarepta Therapeutics | $1.24B | $362.93M |
PTCT | PTC Therapeutics | $937.82M | $135.42M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
KRYS | Krystal Biotech | $50.70M | $83.84M |
IOVA | Iovance Biotherapeutics | $1.19M | $58.55M |
VKTX | Viking Therapeutics | - | - |
MDGL | Madrigal Pharmaceuticals | - | $62.17M |
HEPA | Hepion Pharmaceuticals | - | - |